Key Takeaways & Executive Findings
- •• Advanced scaffold designs and biomaterials significantly enhance cell adhesion, proliferation, and differentiation for tissue regeneration. • Integration of stem cells with growth factors and bioreactor systems improves the functionality and maturation of engineered tissues. • 3D bioprinting and organ-on-chip platforms enable precise spatial control and mimic physiological microenvironments, accelerating drug testing and disease modeling. • Overcoming challenges such as vascularization and immune rejection is crucial for successful clinical translation of tissue-engineered constructs.
Abstract
Tissue engineering has emerged as a promising approach for repairing and regenerating damaged tissues and organs. This comprehensive review examines the current state of human tissue engineering, focusing on the development of advanced scaffolds, cell sources, and bioreactor systems. We discuss the integration of biomaterials with stem cells and growth factors to create functional tissue constructs. The review highlights recent advances in 3D bioprinting and organ-on-chip technologies that mimic native tissue microenvironments. Challenges such as vascularization, immune response, and scalability are addressed. Future directions include personalized medicine and the use of artificial intelligence for optimized tissue design. This review provides a critical analysis of the field and offers insights into clinical translation.
1. Introduction
Tissue engineering is an interdisciplinary field that combines principles of engineering and life sciences to develop biological substitutes that restore, maintain, or improve tissue function. Over the past decades, significant progress has been made in creating functional tissues for regenerative medicine. The core strategy involves the use of scaffolds, cells, and bioactive molecules to guide tissue formation. However, translating these constructs from bench to bedside remains a major challenge due to issues such as vascularization, immune compatibility, and scale-up.
Recent advances in biomaterials, stem cell biology, and manufacturing technologies have opened new avenues for tissue engineering. The emergence of 3D bioprinting and organ-on-chip systems has revolutionized the field by enabling the creation of complex, vascularized tissue constructs with high precision. These technologies not only facilitate the study of disease mechanisms but also provide platforms for drug screening and personalized medicine. This review aims to provide a comprehensive overview of the current models and future directions in human tissue engineering, highlighting key innovations and remaining hurdles.
Loading authentic research manuscript (Pages 1–5)...
Y. Wang, Q. Li, Z. Zhang, H. Chen (2026). Human Tissue Engineering: A Comprehensive Review of Current Models and Future Directions. Chinese Journal of New Drugs. https://doi.org/10.1007/s40831-024-00845-6
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is tissue engineering?
Tissue engineering is an interdisciplinary field that applies principles of engineering and life sciences to create biological substitutes that restore, maintain, or improve tissue function.
What are the key components of tissue engineering?
The key components are scaffolds (biomaterials), cells (often stem cells), and bioactive molecules (growth factors) that together promote tissue regeneration.
How does 3D bioprinting contribute to tissue engineering?
3D bioprinting allows precise spatial placement of cells and biomaterials to create complex, vascularized tissue constructs that mimic native tissue architecture, enhancing functionality and clinical relevance.
What are the main challenges in clinical translation of tissue-engineered products?
Major challenges include achieving adequate vascularization, preventing immune rejection, ensuring long-term stability, and scaling up production to meet clinical demands.
What are the future directions in tissue engineering?
Future directions include personalized medicine using patient-specific cells, integration of artificial intelligence for optimized scaffold design, and development of more sophisticated organ-on-chip models for drug testing.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.